The privatization of Medicago Inc. (TSX: MDG) by Mitsubishi Tanabe Pharma Corporation (TSE: 4508) (MTPC) and Philip Morris Investments B.V. (PMI), an affiliate of Philip Morris International Inc. (NYSE/Euronext Paris: PM) (PMI), for a total enterprise value of $357 million, was completed on September 18, 2013.
Medicago, headquartered in Quebec, Canada, is a clinical-stage biopharmaceutical company developing novel vaccines and therapeutic proteins to address a broad range of infectious diseases.
MTPC, headquartered in Osaka, Japan, is a research-driven pharmaceutical company, specializing in research, development and marketing of pharmaceutical products.
PMI is a leading international tobacco company.
A subsidiary of MTPC, 9284-9686 Québec Inc., acquired, for a consideration of $1.16 per common share in cash, all of the outstanding common shares of Medicago, other than the common shares held by MTPC and PMI, pursuant to the terms of an arrangement agreement. As a result, Medicago has become jointly owned by MTPC (60 per cent) and PMI (40 per cent). PMI, MTPC and 9284-9686 Québec Inc. entered into a joint venture and unanimous shareholders agreement with respect to the governance of Medicago going forward.
Medicago was represented by McCarthy Tétrault LLP with a team led by Philippe Leclerc that included Charles-Antoine Soulière, Myreille Gilbert, Graham Gow (business law), Véronique Wattiez Larose (intellectual property), Christian Meighen and Annie Mailhot-Gamelin (tax); Madeleine Renaud (regulatory), Jean Lortie and Pascale De Meyer (litigation) and Pierre Jolin (labour). Paul, Weiss, Rifkind, Wharton & Garrison LLP was US counsel to Medicago with a team of Adam Givertz (corporate) and Richard Elliott (counsel) and David Mayo and Jenna Harris (tax).
MTPC was represented by Stikeman Elliott LLP with a team led by Steeve Robitaille that included Gayle Noble, Maxime Turcotte, Andrea Cleven, David Tardif, Alexandra Tremblay and Vincent Laurin (M&A/securities); Jonathan Auerbach (intellectual property), Franco Gadoury, Dominic Bédard-Lapointe (tax), Michel Gélinas, Paul Beaudry (regulatory) and Marc-André Coulombe and Frédéric Paré (litigation). Ropes & Gray LLP assisted the acquiror with IP and regulatory matters.
PMI was represented by Heenan Blaikie LLP with a team led by Bruno Caron and Frank Picciola that included Anthony Penhale (securities), Manon Thivierge (tax), Bill Mayo (IP), Adam Goodman (regulatory matters), Stéphanie Normandin and Gregory McLean. PMI was represented in-house by a team led by Hugues DuBois.
Medicago's financial adviser, TD Securities Inc., was represented by Chris Hewat and Lindsay Hooper of Blake, Cassels & Graydon LLP.
Medicago, headquartered in Quebec, Canada, is a clinical-stage biopharmaceutical company developing novel vaccines and therapeutic proteins to address a broad range of infectious diseases.
MTPC, headquartered in Osaka, Japan, is a research-driven pharmaceutical company, specializing in research, development and marketing of pharmaceutical products.
PMI is a leading international tobacco company.
A subsidiary of MTPC, 9284-9686 Québec Inc., acquired, for a consideration of $1.16 per common share in cash, all of the outstanding common shares of Medicago, other than the common shares held by MTPC and PMI, pursuant to the terms of an arrangement agreement. As a result, Medicago has become jointly owned by MTPC (60 per cent) and PMI (40 per cent). PMI, MTPC and 9284-9686 Québec Inc. entered into a joint venture and unanimous shareholders agreement with respect to the governance of Medicago going forward.
Medicago was represented by McCarthy Tétrault LLP with a team led by Philippe Leclerc that included Charles-Antoine Soulière, Myreille Gilbert, Graham Gow (business law), Véronique Wattiez Larose (intellectual property), Christian Meighen and Annie Mailhot-Gamelin (tax); Madeleine Renaud (regulatory), Jean Lortie and Pascale De Meyer (litigation) and Pierre Jolin (labour). Paul, Weiss, Rifkind, Wharton & Garrison LLP was US counsel to Medicago with a team of Adam Givertz (corporate) and Richard Elliott (counsel) and David Mayo and Jenna Harris (tax).
MTPC was represented by Stikeman Elliott LLP with a team led by Steeve Robitaille that included Gayle Noble, Maxime Turcotte, Andrea Cleven, David Tardif, Alexandra Tremblay and Vincent Laurin (M&A/securities); Jonathan Auerbach (intellectual property), Franco Gadoury, Dominic Bédard-Lapointe (tax), Michel Gélinas, Paul Beaudry (regulatory) and Marc-André Coulombe and Frédéric Paré (litigation). Ropes & Gray LLP assisted the acquiror with IP and regulatory matters.
PMI was represented by Heenan Blaikie LLP with a team led by Bruno Caron and Frank Picciola that included Anthony Penhale (securities), Manon Thivierge (tax), Bill Mayo (IP), Adam Goodman (regulatory matters), Stéphanie Normandin and Gregory McLean. PMI was represented in-house by a team led by Hugues DuBois.
Medicago's financial adviser, TD Securities Inc., was represented by Chris Hewat and Lindsay Hooper of Blake, Cassels & Graydon LLP.
Lawyer(s)
Franco Gadoury
Bruno Caron
Madeleine Renaud
Andrea Cleven
Marc-André Coulombe
Philippe Leclerc
Adam Goodman
Pierre Jolin
Gayle Noble
Jean Lortie
Paul Beaudry
Frédéric Paré
Frank L. Picciola
Manon Thivierge
Annie Mailhot-Gamelin
Steeve Robitaille
Christopher A. Hewat
Christian Meighen
Charles-Antoine Soulière
Anthony Penhale
Véronique Wattiez Larose
Maxime Turcotte
Bill Mayo
Jonathan N. Auerbach
David A. Tardif
Michel Gélinas
Firm(s)
McCarthy Tétrault LLP
Paul, Weiss, Rifkind, Wharton & Garrison LLP
Stikeman Elliott LLP
Ropes & Gray LLP
Blake, Cassels & Graydon LLP